FDA 将于3月讨论施贵宝的恩替卡韦申请

zasxz

Antiviral Drugs Advisory CommitteeCenterDateTimeLocationCDERMarch 11, 20058 a.m. - 5 p.m.

Hilton Washington DC North Salons A & B 620 Perry Pkwy. Gaithersburg, MD

Agenda: The committee will discuss new drug applications (NDAs) 21-797 and 21-798, entecavir tablets and entecavir oral solution, respectively, Bristol-Myers Squibb Co., proposed for the treatment of patients with chronic hepatitis B infection (HBV).

Background material and meeting information will become available no later than one business day before the meeting (Simply select the appropriate committee link).

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 25, 2005. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 25, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Angie Whitacre at 301-827-7001 at least 7 days in advance of the meeting.

Contact Person: Anuja Patel, Food and Drug Administration, Center for Drug Evaluation and Research (HFD-21), 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, Rm. 1093), Rockville, Maryland 20857, 301-827-7001, Fax: 301-827-6776, e-mail: [email protected], or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512531. Please call the Information Line for up-to-date information on this meeting.

上香

不知道有没有战友对entecavir有所了解

zasxz

有个战友好像用过，不知道最近如何了。好像是II期试验。

国外的数据你可以从我的文章中找到很多。